Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manzoor A Mir

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|August 31, 2024
Mutant P53 modulation by cryptolepine through cell cycle arrest and apoptosis in triple negative breast cancerHina Qayoom, Manzoor A Mir
Expert Opinion on Therapeutic Targets|July 16, 2008
Signaling through CD80: an approach for treating lymphomasManzoor A Mir, Javed N Agrewala
Immunologic Research|April 2, 2023
Targeting tumor microenvironment using tumor-infiltrating lymphocytes as therapeutics against tumorigenesisHina Qayoom, Shazia Sofi, Manzoor A Mir
Breast Cancer (Tokyo, Japan)|March 4, 2021
Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectivesUmar Mehraj, Hina Qayoom, Manzoor A Mir
Discover Oncology|August 10, 2025
Integrative systems biology and in-vitro analysis of cryptolepine's therapeutic role in breast cancerHina Qayoom, Pankaj Keshari, Manzoor A Mir
Cancer Biomarkers : Section a of Disease Markers|May 2, 2022
Expression pattern and prognostic significance of CDKs in breast cancer: An integrated bioinformatic studyUmar Mehraj, Shazia Sofi, Bader Alshehri, et al.
Future Oncology (London, England)|August 3, 2021
An insight into the cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancerHina Qayoom, Nissar A Wani, Bader Alshehri, et al.
Current Pharmaceutical Biotechnology|December 24, 2021
Strategies Employed to Evade the Host Immune Response and the Mechanism of Drug Resistance in <i>Mycobacterium tuberculosis</i>: In Search of Finding New TargetsBashir A Sheikh, Basharat A Bhat, Zahoor Ahmad, et al.
Human Antibodies|July 20, 2019
Nanobodies: The "Magic Bullets" in therapeutics, drug delivery and diagnosticsManzoor A Mir, Umar Mehraj, Bashir Ahmad Sheikh, et al.
Future Microbiology|August 4, 2022
Manipulation and exploitation of host immune system by pathogenic <i>Mycobacterium tuberculosis</i> for its advantageManzoor A Mir, Bilkees Mir, Manoj Kumawat, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|August 31, 2024
Mutant P53 modulation by cryptolepine through cell cycle arrest and apoptosis in triple negative breast cancerHina Qayoom, Manzoor A Mir
Expert Opinion on Therapeutic Targets|July 16, 2008
Signaling through CD80: an approach for treating lymphomasManzoor A Mir, Javed N Agrewala
Immunologic Research|April 2, 2023
Targeting tumor microenvironment using tumor-infiltrating lymphocytes as therapeutics against tumorigenesisHina Qayoom, Shazia Sofi, Manzoor A Mir
Breast Cancer (Tokyo, Japan)|March 4, 2021
Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectivesUmar Mehraj, Hina Qayoom, Manzoor A Mir
Discover Oncology|August 10, 2025
Integrative systems biology and in-vitro analysis of cryptolepine's therapeutic role in breast cancerHina Qayoom, Pankaj Keshari, Manzoor A Mir
Cancer Biomarkers : Section a of Disease Markers|May 2, 2022
Expression pattern and prognostic significance of CDKs in breast cancer: An integrated bioinformatic studyUmar Mehraj, Shazia Sofi, Bader Alshehri, et al.
Future Oncology (London, England)|August 3, 2021
An insight into the cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancerHina Qayoom, Nissar A Wani, Bader Alshehri, et al.
Current Pharmaceutical Biotechnology|December 24, 2021
Strategies Employed to Evade the Host Immune Response and the Mechanism of Drug Resistance in <i>Mycobacterium tuberculosis</i>: In Search of Finding New TargetsBashir A Sheikh, Basharat A Bhat, Zahoor Ahmad, et al.
Human Antibodies|July 20, 2019
Nanobodies: The "Magic Bullets" in therapeutics, drug delivery and diagnosticsManzoor A Mir, Umar Mehraj, Bashir Ahmad Sheikh, et al.
Future Microbiology|August 4, 2022
Manipulation and exploitation of host immune system by pathogenic <i>Mycobacterium tuberculosis</i> for its advantageManzoor A Mir, Bilkees Mir, Manoj Kumawat, et al.
Pageof 3